Inhaled Nintedanib Shows Early Safety in IPF
Adults with pulmonary fibrosis who struggle with the oral pill may one day have an inhaled option, though data are still early.
Updated on Nov. 3, 2026 in Asthma

MannKind Corp. announced positive results from a Phase 1b study within its INFLO-1 clinical trial, which evaluates an inhaled dry powder form of nintedanib for idiopathic pulmonary fibrosis (IPF). The study reported no drug-related diarrhea, nausea, or vomiting, no serious adverse events, and no discontinuations.
Why it matters
Roughly three out of four IPF patients are not receiving an approved antifibrotic therapy, often because the oral form of nintedanib is hard to tolerate. An inhaled version aims to deliver the drug mainly to the lungs, which could make treatment more feasible for patients who cannot tolerate the pill.
This is a Phase 1b clinical trial within the INFLO-1 program, and the reported results focus on safety, with no drug-related gastrointestinal side effects, serious adverse events, or discontinuations. The stub does not provide sample size or efficacy measures, so the findings are early and preliminary.
The players
MannKind Corp.
A biopharmaceutical company that develops inhaled therapies, including the Technosphere platform behind the FDA-approved products Afrezza and Tyvaso DPI.
The details
The inhaled formulation uses MannKind's Technosphere platform and Dreamboat dry powder inhaler, and it is designed to deliver nintedanib directly into the lungs while limiting exposure to the rest of the body. The oral form circulates through the whole body, which is associated with significant gastrointestinal side effects. The Global Phase 2 INFLO-2 study is enrolling IPF patients across global sites and will evaluate the inhaler over a 12-week controlled period followed by a 24-week extension.
Timeline
Phase 1b INFLO-1 results were announced on November 3, 2026.
INFLO-2 patient follow-up is planned for approximately nine months to generate safety and efficacy data.
Health Landscape
Nintedanib is an established antifibrotic therapy for IPF in oral form, but many patients cannot tolerate it, leaving a large share untreated. An inhaled delivery route that targets the lungs is an emerging approach to widening access to antifibrotic treatment.
If you or a loved one has IPF and has struggled with the side effects of oral nintedanib, an inhaled option is an emerging approach worth discussing with a pulmonologist once more data are available. Anyone with a lung condition should talk with their doctor before considering any change in treatment.
The takeaway
Inhaled delivery aims to put medication where IPF affects the body most, and the early Phase 1b safety results are encouraging. Patients interested in clinical trials can ask their pulmonologist whether enrollment in the INFLO-2 study is an option.
What happens next
The Global Phase 2 INFLO-2 study is enrolling IPF patients across global sites and will provide longer-term safety and efficacy data over approximately nine months of follow-up.
Further reading
For broader context on inhaled drug delivery for lung conditions, explore our Asthma coverage.
Source note: This article includes information reported by Westfair Communications.


